Table 1 Breast cancer patients’ clinicopathological data of the testing and validation cohort #1
From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer
Clinicopathological features | Testing cohort | Validation cohort #1 |
|---|---|---|
Patients (n) | 16 | 82 |
Age median (range) | 58 (35–78) | 49 (28–76) |
Molecular subtypea (%) | ||
Luminal A-Like | 4 (25.0) | 19 (23.2) |
Luminal B-Like | 12 (75.0) | 58 (70.7) |
HER2-enriched | – | 1 (1.2) |
Basal-like/TNBC | – | 4 (4.9) |
Histological type (%) | ||
Invasive carcinoma of NST | 13 (81.2) | 73 (89.0) |
Invasive lobular carcinoma | 3 (18.8) | – |
Other special subtype carcinoma | – | – |
Mixed type carcinoma | – | 9 (11.0) |
Grade (%) | ||
G1 | 2 (12.5) | 4 (4.9) |
G2 | 4 (25.0) | 43 (52.4) |
G3 | 8 (50.0) | 35 (42.7) |
Gx | 2 (12.5) | – |
ER receptor status (%) | ||
Positive | 16 (100.0) | 77 (93.9) |
Negative | – | 5 (6.1) |
PR receptor status (%) | ||
Positive | 10 (62.5) | 65 (79.3) |
Negative | 6 (37.5) | 17 (20.7) |
HER2 receptor status (%) | ||
Positive | 3 (18.8) | 15 (18.3) |
Negative | 13 (81.2) | 67 (81.7) |
T Stage (%) | ||
T1 | 4 (25.0) | 20 (24.4) |
T2 | 9 (56.2) | 52 (63.4) |
T3 | 1 (6.3) | 5 (6.1) |
T4 | 2 (12.5) | 3 (3.7) |
Tx | – | 2 (2.4) |
N Stage (%) | ||
N0 | 5 (31.2) | 18 (22.0) |
N1 | 7 (43.8) | 33 (40.2) |
N2 | 2 (12.5) | 16 (19.5) |
N3 | 2 (12.5) | 13 (15.9) |
Nx | – | 2 (2.4) |
Stage (%) | ||
I | 3 (18.8) | 10 (12.2) |
II | 8 (50.0) | 34 (41.5) |
III | 5 (31.2) | 24 (29.3) |
IV | – | 12 (14.6) |
Not determined | – | 2 (2.4) |